IC
CYTK icon

Ikarian Capital’s Cytokinetics CYTK Stock Holding History

Ikarian Capital’s Portfolio CYTK Stock Details CYTK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-283,572
Closed -$18.7M – 164
2026
Q1 		$18.7M Buy
283,572
+110,900
+64% +$7.05M 1.52% 16
2025
Q4 		$11M Sell
172,672
-50,002
-22% -$3.11M 0.86% 33
2025
Q3 		$12.2M Sell
222,674
-10,790
-5% -$445K 1.24% 18
2025
Q2 		$7.71M Buy
233,464
+83,482
+56% +$2.9M 1.48% 23
2025
Q1 		$6.03M Hold
149,982
– – 0.74% 30
2024
Q4 		$7.06M Sell
149,982
-20,165
-12% -$1.05M 0.96% 28
2024
Q3 		$8.98M Hold
170,147
– – 1.25% 21
2024
Q2 		$9.22M Buy
170,147
+25,000
+17% +$1.51M 1.61% 18
2024
Q1 		$10.2M Buy
145,147
+115,147
+384% +$8.91M 1.12% 28
2023
Q4 		$2.5M Buy
+30,000
New +$1.09M 0.23% 81
2023
Q2 		– Sell
-55,666
Closed -$1.96M – 145
2023
Q1 		$1.96M Buy
+55,666
New +$2.27M 0.44% 58
2021
Q3 		– Sell
-120,895
Closed -$2.39M – 228
2021
Q2 		$2.39M Sell
120,895
-6,105
-5% -$143K 0.19% 120
2021
Q1 		$2.95M Sell
127,000
-100,000
-44% -$2.14M 0.1% 173
2020
Q4 		$4.72M Buy
227,000
+172,000
+313% +$3.14M 0.21% 98
2020
Q3 		$1.19M Buy
+55,000
New +$1.29M 0.09% 126

Other funds holding CYTK

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Ikarian Capital's CYTK Position: Q2 2026 in Review

Ikarian Capital sold out of Cytokinetics (CYTK) in Q2 2026, closing a stake of 283,572 shares — an estimated $18.7M sold.

Ikarian Capital first reported a position in CYTK in Q3 2020 and held it in 15 quarters. The position peaked at $18.7M in Q1 2026. 482 funds tracked by Wall St. Rank hold CYTK as of Q2 2026.

  • Ikarian Capital reported no remaining Cytokinetics position as of Q2 2026 after selling out during the quarter.
  • Ikarian Capital sold 283,572 Cytokinetics shares in Q2 2026, an estimated $18.7M.
  • Ikarian Capital first reported a position in Cytokinetics in Q3 2020 and held it in 15 quarters.
  • Ikarian Capital's Cytokinetics position peaked at $18.7M in Q1 2026.
  • 482 funds tracked by Wall St. Rank held Cytokinetics as of Q2 2026.

Based on Ikarian Capital's 13F filing for Q2 2026, filed 14 Aug 2026.